{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:14:51Z","timestamp":1790615691524,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40744-024-00654-5","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T14:01:44Z","timestamp":1710770504000},"page":"617-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase\u00a03 KEEPsAKE\u00a01 Randomized Clinical Trial"],"prefix":"10.1007","volume":"11","author":[{"given":"Lars Erik","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Keiserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"McCasland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-8511","authenticated-orcid":false,"given":"Douglas","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzefa","family":"Photowala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Drogaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"654_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"key":"654_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"654_CR3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","volume":"76","author":"LE Kristensen","year":"2017","unstructured":"Kristensen LE, Jorgensen TS, Christensen R, et al. Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;76:1495\u2013501.","journal-title":"Ann Rheum Dis"},{"key":"654_CR4","first-page":"14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:14\u20137.","journal-title":"Ann Rheum Dis"},{"key":"654_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","volume":"84","author":"AB Gottlieb","year":"2021","unstructured":"Gottlieb AB, Merola JF. Axial psoriatic arthritis: an update for dermatologists. J Am Acad Dermatol. 2021;84:92\u2013101.","journal-title":"J Am Acad Dermatol"},{"key":"654_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"654_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/acr.20162","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Cook R, Lee KA, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010;62:970\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"654_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","volume":"73","author":"E Theander","year":"2014","unstructured":"Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73:407\u201313.","journal-title":"Ann Rheum Dis"},{"key":"654_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551\u201360.","journal-title":"N Engl J Med"},{"key":"654_CR10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7:778\u201391.","journal-title":"MAbs"},{"key":"654_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE\u00a01 trial. Ann Rheum Dis. 2022;81:225\u201331.","journal-title":"Ann Rheum Dis"},{"key":"654_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6stor","year":"2022","unstructured":"\u00d6stor A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE\u00a02 trial. Ann Rheum Dis. 2022;81:351\u20138.","journal-title":"Ann Rheum Dis"},{"key":"654_CR13","first-page":"e389","volume":"36","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Soliman AM, Papp K, et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE\u00a01. J Eur Acad Dermatol Venereol. 2022;36:e389\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"654_CR14","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","volume":"62","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE\u00a01 study. Rheumatology (Oxford). 2023;62:2113\u201321.","journal-title":"Rheumatology (Oxford)"},{"key":"654_CR15","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","volume":"62","author":"A \u00d6stor","year":"2023","unstructured":"\u00d6stor A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE\u00a02 study. Rheumatology (Oxford). 2023;62:2122\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"654_CR16","first-page":"ii61","volume":"64","author":"DVD Heijde","year":"2005","unstructured":"Heijde DVD, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005;64:ii61\u20134.","journal-title":"Ann Rheum Dis"},{"key":"654_CR17","first-page":"123","volume":"34","author":"SE Cassell","year":"2007","unstructured":"Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34:123\u20139.","journal-title":"J Rheumatol"},{"key":"654_CR18","doi-asserted-by":"publisher","first-page":"A127","DOI":"10.1016\/j.jval.2016.03.519","volume":"19","author":"S Hudgens","year":"2016","unstructured":"Hudgens S, Sundaram M, Williams D. Evaluation of a novel clinician reported outcome in nail psoriasis. Value Health. 2016;19:A127.","journal-title":"Value Health"},{"key":"654_CR19","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38:2461\u20135.","journal-title":"J Rheumatol"},{"key":"654_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/art.40391","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, FitzGerald O, Merola JF, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol. 2018;70:345\u201355.","journal-title":"Arthritis Rheumatol"},{"key":"654_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186:466\u201375.","journal-title":"Br J Dermatol"},{"key":"654_CR22","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1038\/s41598-023-31709-2","volume":"13","author":"K Agyapon-Ntra","year":"2023","unstructured":"Agyapon-Ntra K, McSharry PE. A global analysis of the effectiveness of policy responses to COVID-19. Sci Rep. 2023;13:5629.","journal-title":"Sci Rep"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00654-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00654-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00654-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:30:54Z","timestamp":1716391854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00654-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00654-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lars Erik Kristensen has received honoraria or fees for serving as a speaker or consultant from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB. He has also received IIT research grants from Lilly, Novartis, Pfizer, and UCB. Mauro Keiserman has served as a speaker for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; was a consultant for AbbVie, Bristol\u00a0Myers Squibb, GlaxoSmithKline, MSD, Biogen, Sanofi, and Novartis; and receives grant\/research support from AbbVie, Bristol\u00a0Myers Squibb, GlaxoSmithKline, MSD, Biogen, Sanofi, and Novartis. Kim Papp has received research funds from AbbVie, Aceleryn, Amgen, Arcutis, Bausch Health, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Dermavant, Forward Pharma, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. He is a consultant for AbbVie, Aceleryn, Amgen, Arcutis, Astellas, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Dermavant, Forward Pharma, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Meiji Seika Pharma, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sandoz, Sanofi Genzyme, Stiefel, Sun Pharma, Takeda, and UCB. He is a speaker for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB. He is a committee member for PSOLAR (Psoriasis Longitudinal Assessment and Registry) and PURE (registry of patients with moderate-to-severe chronic plaque psoriasis in Latin America and Canada). Leslie McCasland has received fees for serving on an advisory board from Lilly. Douglas White has received honoraria or fees for serving on advisory boards or as a speaker or consultant from AbbVie. Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Michael Chen, and Byron Padilla are full-time employees of AbbVie, and may hold AbbVie stock or stock options. Ahmed M. Soliman is a full-time employee of AbbVie, may hold AbbVie stock or stock options, and is a coinventor on AbbVie patents. Frank Behrens has received research grants, honoraria, or fees for serving as a consultant or speaker from AbbVie, Amgen, Affibody, Acelyrin, BMS, Boehringer Ingelheim, Chugai, Celltrion, Galapagos, Genzyme, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, MoonLake, Novartis, Pfizer, Roche, Sandoz and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol, informed consent forms, and recruitment materials were approved by the independent ethics committee or institutional review board at each study site before patient enrollment began (Supplementary Table\u00a01). The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent before entering the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}